Boston Therapeutics rakes in $150m Series C

Frazier Life Sciences and Lightspeed Venture Partners led the round.

16 July 2024•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals & Exits Briefs